AAV Vector Market Size, Share, By Offering (Product Type, Services), Serotype (AV1, AAV2, AAV5, AAV6, and Others), Gene Delivery Method (Ex Vivo, and In Vivo), Target Therapeutic Area (Genetic Disorders, Hematological Disorders, Infectious Disorders, Metabolic Disorders, Ophthalmic Disorders, Muscle Disorders, Neurological Disorders, and Others), Application Area (Gene Therapy, Cell Therapy, and Vaccines), End-User (Hospitals, Clinics, Research Institutes, Biopharmaceutical Companies, and Others), and Region - Trends, Analysis, and Forecast till 2035

• Adverum Biotechnologies, Inc.
• Gene Universal, Inc.
• Oxford Biomedica PLC
• SK pharmteco Inc.
• Aldevron LLC.
• WuXi AppTec
• Isolere Bio, Inc.
• Dyno Therapeutics
• Polyplus
• Charles River Laboratories
• OriGene Technologies, Inc.
• Thermo Fisher Scientific Inc.
• Avirmax CMC
• AGC Biologics
• Voyager Therapeutics Inc.
• ACROBiosystems

Recent News:

• Avirmax CMC, a leader in the innovation and manufacture of adeno-associated virus (AAV) vector-mediated biotherapeutics, announced the successful delivery to its first client with Good Manufacturing Practice (GMP) lots of AAV vector product trial use, in July 2024. This milestone marks a significant achievement in Avirmax CMC's mission to provide high-quality gene therapy solutions.
• Charles River Laboratories International, Inc., announced the launch of its reference materials for adeno associated virus (AAV) and lentiviral vector (LVV) portfolio, in May 2024. It was designed to streamline Cell and Gene Therapy (CGT) research and development as it scaled to Good Manufacturing Practice- (GMP) quality.